EUVIMEDEUVIMED entdecken
Crossref

BRD4-binding enhancer promotes CRC progression by interacting with YY1 to activate the Wnt pathway through upregulation of TCF7L2

Biao Duan, Xuwei Zhou, Xiaoyi Zhang, Fenglan Qiu, Shaoqing Zhang, Yue Chen, Jun Yang, Juan Wang, Wenfu Tan

Biochemical Pharmacology · 2023

DOI: 10.1016/j.bcp.2023.115877 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Biao Duan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China. Electronic address: 20111030073@fudan.edu.cn. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Wnt Signaling Pathway. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal carcinoma (CRC), one of the most life-threatening cancer types, is associated with aberrant expression of epigenetic modifiers and activation of the Wnt pathway. However, the role of epigenetic regulators in driving cancer cell proliferation and their potential as therapeutic targets affecting the Wnt pathway remain unclear. In this study, BRD4 was found to promote the progression of CRC both in vitro and in vivo. The expression of BRD4 correlated with shortened CRC patient survival. In addition, BRD4 function was strongly correlated with the Wnt pathway, but rather through regulation of TCF7L2 at transcriptional levels. BRD4 and H3K27ac have overlapping occupancies in the cis-regulatory elements of TCF7L2, suggesting enhancer-based epigenetic regulation. Numerous YY1 binding sites were found in the abovementioned region. YY1 recruited BRD4 to bind to cis-regulatory elements of TCF7L2, thereby regulating the expression of TCF7L2. Altogether, this study validates that BRD4 performs a canonical epigenetic regulatory function in CRC and can be used in the treatment of Wnt pathway-dependent CRC or other malignancies with clinically available bromodomain inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsWnt Signaling PathwayHumansCell Cycle ProteinsCell Line, TumorCell ProliferationEpigenesis, GeneticGene Expression Regulation, NeoplasticNuclear ProteinsTranscription Factor 7-Like 2 ProteinTranscription FactorsUp-RegulationBromodomain Containing ProteinsYY1 Transcription Factor

Stichwörter der Autor:innen

BRD4Colorectal carcinomaEpigenetic regulationTCF7L2Wnt pathway

Substanzen

Cell Cycle ProteinsNuclear ProteinsTranscription Factor 7-Like 2 ProteinTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsTCF7L2 protein, humanYY1 protein, humanYY1 Transcription Factor

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China. Electronic address: 20111030073@fudan.edu.cn.
  • Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China.
  • Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China. Electronic address: wftan@fudan.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Duan, B., Zhou, X., Zhang, X., Qiu, F., Zhang, S., Chen, Y., Yang, J., Wang, J., & Tan, W. (2023). BRD4-binding enhancer promotes CRC progression by interacting with YY1 to activate the Wnt pathway through upregulation of TCF7L2. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115877

Vancouver

Duan B, Zhou X, Zhang X, Qiu F, Zhang S, Chen Y, et al. BRD4-binding enhancer promotes CRC progression by interacting with YY1 to activate the Wnt pathway through upregulation of TCF7L2. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115877

BibTeX
@article{Duan2023,
  author = {Duan, Biao and Zhou, Xuwei and Zhang, Xiaoyi and Qiu, Fenglan and Zhang, Shaoqing and Chen, Yue and Yang, Jun and Wang, Juan and Tan, Wenfu},
  title = {BRD4-binding enhancer promotes CRC progression by interacting with YY1 to activate the Wnt pathway through upregulation of TCF7L2},
  journal = {Biochemical Pharmacology},
  year = {2023},
  doi = {10.1016/j.bcp.2023.115877}
}
Kostenlos starten →